Biotech and healthcare look set to deliver eternal wealth, if not health

- by JOhn butcher
- 01 Aug 2004

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

The recent sell-off in the listed biotech sector, following a strong 2003, has highlighted attractive buying opportunities for specialist hedge funds, according to managers in the niche strategy.

In the last 11 months of 2003, the MSCI World index outperformed the Dow Jones STOXX 600 Pharmaceuticals Biotechnology IG Price Index by 4.92%. However, the pharmaceutical and biotechnology index still posted healthy returns of 12.91%, according to Bloomberg, against MSCI World's 15.33%.

The rude health

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to print this content. Please contact info@risk.net to find out more.

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

More on Hedge funds

Investing

JP Morgan warns hedge funds to expect intraday margin calls

US bank may demand variation margin ‘up to seven’ times a day after Archegos default

13 Jul 2021

Hedge funds

Alternative markets give edge to Florin Court strategy

By concentrating on exotic and alternative markets, Florin Court Capital Fund has sidestepped overcrowding and correlation to the main trend following commodity trading advisers, offering investors a diversified alternative to the standard systemic macro…

24 Aug 2020

Hedge funds

Global macro views combine with quantitative models to produce consistent returns

The team behind River and Mercantile Group’s global macro strategy team operates under two key principles: that macro is the most important aspect of any investment decision and that decision-making should incorporate both systematic and discretionary…

21 Apr 2020

Hedge funds

On the offensive – Seeking a new edge, buy-side invests in portfolio and risk analytics

A fast-moving, headstrong hedge fund – hit by rare losses after a black swan event touched on an overweight country exposure – ponders adding fresh quantitative expertise. Much to traders’ chagrin, the chief investment officer and chief operating officer…